Clinical Trial Update: A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lumicitabine (JNJ-64041575) in hospitalized infants and children with respiratory syncytial virus; study terminated with posted results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Infection
• Respiratory Syncytial Virus Infection

Drugs mentioned

• Lumicitabine (lumicitabine)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Respiratory Syncytial Viruses | Phase 2 | Status: TERMINATED | Results posted: 2019-12-05